These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 3724934)

  • 21. [Studies of urinary risk factors in urolithiasis].
    Ebisuno S; Kitagawa M; Morimoto S; Miyazaki Y; Minakata S; Yasukawa S; Fukatani T; Ohkawa T
    Hinyokika Kiyo; 1985 Jan; 31(1):1-15. PubMed ID: 3993484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The urinary excretion of oxalic acid and magnesium in oxalate urolithiasis.
    Takasaki E; Shimano E
    Invest Urol; 1967 Nov; 5(3):303-12. PubMed ID: 6073639
    [No Abstract]   [Full Text] [Related]  

  • 23. Calcium oxalate crystalluria and inhibitors of crystallization in recurrent renal stone-formers.
    Robertson WG; Peacock M
    Clin Sci; 1972 Oct; 43(4):499-506. PubMed ID: 4653589
    [No Abstract]   [Full Text] [Related]  

  • 24. Seasonal variation of urinary calcium and oxalate excretion, serum 25(OH)D3 and albumin level in relation to renal stone formation.
    Elomaa I; Karonen SL; Kairento AL; Pelkonen R
    Scand J Urol Nephrol; 1982; 16(2):155-61. PubMed ID: 7123167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of oxalate and calcium oxalate activity and formation product ratio in patients with renal stones before and during treatment.
    Peña JC; Monforte MF; Briceño A
    J Urol; 1987 Nov; 138(5):1137-40. PubMed ID: 3669156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Excretion of urinary calcium and oxalate on three diets in patients with urolithiasis.
    Juuti M; Alhava EM
    Ann Clin Res; 1980 Dec; 12(6):320-5. PubMed ID: 7235608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemical factors important to calcium nephrolithiasis: evidence for impaired hydroxycarboxylic acid absorption causing hyperoxaluria.
    Cowley DM; McWhinney BC; Brown JM; Chalmers AH
    Clin Chem; 1987 Feb; 33(2 Pt 1):243-7. PubMed ID: 3802507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Renal oxalate excretion following oral oxalate load in patients with urinary calculus disease and healthy controls].
    Ebisuno S; Morimoto S; Yoshida T; Fukatani T; Yasukawa S; Okawa T
    Hinyokika Kiyo; 1986 Dec; 32(12):1773-9. PubMed ID: 3825824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recent data on the urinary excretion of oxalic acid in oxalic renal lithiasis].
    Thomas J; Melon JM; Thomas E; Steg A; Desgrez P; Aboulker P
    Ann Urol (Paris); 1972 Feb; 6(1):31-3. PubMed ID: 5012700
    [No Abstract]   [Full Text] [Related]  

  • 30. Reduction of urine oxalate during long-term thiazide therapy in patients with calcium urolithiasis.
    Cohanim M; Yendt ER
    Invest Urol; 1980 Sep; 18(2):170-3. PubMed ID: 7410033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of supersaturation levels and crystallization rates of calcium oxalate from urines of normal humans and stone formers: effects of nondialyzable materials.
    Gill WB; Roma MJ
    J Surg Res; 1976 Jul; 21(1):45-9. PubMed ID: 933515
    [No Abstract]   [Full Text] [Related]  

  • 32. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methylene blue in renal calculi. Results of five-year study.
    Smith MJ
    Urology; 1975 Dec; 6(6):676-9. PubMed ID: 1202715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Oxaluria in urinary lithiasis].
    Thomas J; Charransol G; Barthelemy C; Thomas E; Legrand JC; Desgrez P; Steg A
    Presse Med; 1983 Sep; 12(32):1991-4. PubMed ID: 6225103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The protective role of eicosapentaenoic acid [EPA] in the pathogenesis of nephrolithiasis.
    Buck AC; Davies RL; Harrison T
    J Urol; 1991 Jul; 146(1):188-94. PubMed ID: 2056589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of calcium restriction on renal excretion of oxalate and the probability of stones in the various pathophysiological groups with calcium stones.
    Bataille P; Charransol G; Gregoire I; Daigre JL; Coevoet B; Makdassi R; Pruna A; Locquet P; Sueur JP; Fournier A
    J Urol; 1983 Aug; 130(2):218-23. PubMed ID: 6876264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The urinary response to an oral oxalate load in recurrent calcium stone formers.
    Krishnamurthy MS; Hruska KA; Chandhoke PS
    J Urol; 2003 Jun; 169(6):2030-3. PubMed ID: 12771711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dietary management of urinary risk factors in renal stone formers.
    Rao PN; Prendiville V; Buxton A; Moss DG; Blacklock NJ
    Br J Urol; 1982 Dec; 54(6):578-83. PubMed ID: 6295538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urine oxalate levels in a New Zealand reference population and renal stone formers.
    Larking P; Lovell-Smith CJ; Hocken AG
    N Z Med J; 1983 Aug; 96(737):606-7. PubMed ID: 6575312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical studies on the recurrence of urolithiasis: (1). Influence of diet on urinary excretion of the stone forming constituents].
    Murayama T; Taguchi H
    Hinyokika Kiyo; 1987 Sep; 33(9):1321-30. PubMed ID: 3434487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.